Long-Term Use of Relacorilant for Cushing Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial team or your doctor.
Is relacorilant safe for long-term use in humans?
Relacorilant has been studied for safety in patients with Cushing syndrome, and it does not cause prolongation of the heart's QT interval (a measure of heart rhythm). It is a selective glucocorticoid receptor modulator, meaning it targets specific receptors without affecting others, which may reduce side effects.12345
How is the drug Relacorilant unique in treating Cushing Syndrome?
Relacorilant is unique because it is a selective glucocorticoid receptor modulator, meaning it specifically targets and modulates the glucocorticoid receptor without affecting the progesterone receptor, which helps avoid certain side effects seen with other treatments. This selectivity may offer a better safety profile, particularly in avoiding heart-related side effects and issues related to glucose metabolism.12367
What data supports the effectiveness of the drug Relacorilant for Cushing Syndrome?
Who Is on the Research Team?
Katherine Araque, MD, MSCR
Principal Investigator
Corcept Therapeutics
Are You a Good Fit for This Trial?
This trial is for patients with Cushing Syndrome who have finished a previous Corcept-sponsored relacorilant study and took their medication at least 80% of the time. They should not have dropped out early, nor should they have uncontrolled thyroid issues, poorly controlled high blood pressure, or severe kidney failure.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Open-label extension
Participants continue therapy with relacorilant for long-term safety evaluation
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Relacorilant
Find a Clinic Near You
Who Is Running the Clinical Trial?
Corcept Therapeutics
Lead Sponsor
Dr. Joseph K. Belanoff
Corcept Therapeutics
Chief Executive Officer since 2014
MD from Stanford University
Dr. William Guyer
Corcept Therapeutics
Chief Medical Officer since 2021
PharmD